BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6689678)

  • 1. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism.
    Ho KY; Smythe GA; Duncan M; Lazarus L
    J Clin Endocrinol Metab; 1984 Jan; 58(1):128-33. PubMed ID: 6689678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
    Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
    Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal lactotroph sensitivity to graded low-dose dopamine infusions in pathological hyperprolactinemia.
    Ho KY; Smythe GA; Lazarus L
    Neuroendocrinology; 1986; 43(2):175-81. PubMed ID: 3724984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
    Serri O; Kuchel O; Buu NT; Somma M
    J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia.
    Webb CB; Thominet JL; Barowsky H; Berelowitz M; Frohman LA
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1089-93. PubMed ID: 6841551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-induced prolactin release in women with pathological hyperprolactinemia.
    Nicoletti I; Ambrosi F; Pagliacci MC; Pelicci G; Giammartino C; Maggio D; Fedeli L; Filipponi P
    Horm Metab Res; 1987 Mar; 19(3):125-9. PubMed ID: 3106177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
    Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
    Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea.
    Giammartino C; Ambrosi F; Pelicci G; Pagliacci MC; Fedeli L; Nicoletti I
    Horm Metab Res; 1988 Jan; 20(1):44-8. PubMed ID: 3131222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic clearance and production rates of prolactin in man.
    Cooper DS; Ridgway EC; Kliman B; Kjellberg RN; Maloof F
    J Clin Invest; 1979 Dec; 64(6):1669-80. PubMed ID: 583048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible thyrotrophs insensitivity to dopamine in hyperprolactinaemic amenorrhoeic patients.
    Nyboe Andersen A; Hagen C; Boesgaard S; Eldrup E; Djursing H
    Horm Metab Res; 1989 Jun; 21(6):328-30. PubMed ID: 2777190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
    Hanew K; Sato S; Sasaki A; Goh M; Shimizu Y; Murakami O; Yoshinaga K
    Endocrinol Jpn; 1985 Dec; 32(6):811-7. PubMed ID: 3938732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
    Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
    Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
    Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
    J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic studies of highly purified human prolactin in normal human subjects.
    Molitch ME; Raiti S; Baumann G; Belknap S; Reichlin S
    J Clin Endocrinol Metab; 1987 Aug; 65(2):299-304. PubMed ID: 3597709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dopaminergic activity inhibits basal and metoclopramide-stimulated prolactin and thyrotropin secretion.
    Agner T; Hagen C; Andersen AN; Djursing H
    J Clin Endocrinol Metab; 1986 Apr; 62(4):778-82. PubMed ID: 3949956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.
    Martin MC; Weiner RI; Monroe SE; Roberts JM; Licko V; Jaffe RB
    J Clin Endocrinol Metab; 1984 Sep; 59(3):485-90. PubMed ID: 6746862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation.
    Quigley ME; Judd SJ; Gilliland GB; Yen SS
    J Clin Endocrinol Metab; 1979 Apr; 48(4):718-20. PubMed ID: 429515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia.
    Genazzani AR; Cavagnini F; Picotti GB; Ghigo E; De Leo V; Galva MD; Maraschini C; Muller EE
    J Clin Endocrinol Metab; 1983 Dec; 57(6):1159-63. PubMed ID: 6630411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.